Metastatic Prostate Cancer
Conditions
Keywords
PSMA positive metastatic prostate cancer
Brief summary
A Study to Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry of ZA-001, an Alpha-particle-emitting (At211) Radiopharmaceutical, in metastatic castration resistant prostate cancer
Interventions
DRUGZA-001
Study drug ZA-001 administered via intravenous injection.
Sponsors
Sichuan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Participants provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements. 2. Participants must be ≥18 years of age and competent to give informed consent. 3. Participants must have progressive mCRPC with histologically or cytologically confirmed adenocarcinoma of the prostate. Participants must have documented PSA and/or radiographic progression. 4. Participants must have Gallium 68 PSMA-11 (Ga 68 PSMA-11) Positron Emission Tomography (PET)/Computed Tomography (CT) prostate-specific membrane antigen (PSMA) positive lesions ≤ 30 days prior to beginning study therapy. 5. Participant has not received any form of prostate-cancer directed therapy since undergoing screening PSMA scan. 6. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 7. Participants must have a life expectancy of more than 3 months. 8. Effective castration with testosterone level of \<50 ng/dL and plan to continue with chronic medical or surgical castration. 9. Participants must have adequate hematological and organ function.
Exclusion criteria
1. Participants with any medical condition or other circumstances that, in the opinion of the investigator, would preclude participation in this study, compromise obtaining reliable data, achieving study objectives, or completion. 2. Pathological findings consistent with small cell and/or neuroendocrine carcinoma of the prostate or any other histology not consistent with prostate adenocarcinoma. 3. Participants with any PSMA-negative metastatic lesion these criteria were ineligible. 4. Less than 4 weeks since last myelosuppressive therapy (including prior radiotherapy or prior treatment with 223Radium, 89Strontium or 153Samarium containing compounds). 5. With active or uncontrolled infection. 6. Have used any other investigational drugs within 4 weeks or 5 half-lives (whichever is shorter) prior to the start of the study treatment, or have used any investigational medical devices within 4 weeks prior to the start of the study treatment, and plan to receive other investigational drugs or medical devices during the course of this study. 7. Previously known to have a history of allergy, hypersensitivity, or intolerance to radioactive drugs; or known to be allergic to ethanol. 8. Participants who have a pregnant partner or are capable of fathering a child and who are unwilling to take precautions to prevent potential harm to the fetus or prevent pregnancy during and for 90 days after discontinuation of study treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The absorbed radiation doses (Gray [Gy] /Megabecquerel [MBq] )for whole body and organ | 24 hours | SPECT/CT will be scanned following administration of the ZA-001 |
| Adverse Event | 1 week | Number of participants with Adverse Events as a measure of safety and tolerability |
Countries
China
Outcome results
None listed